EN | 中文

MicuRx discovers and develops novel antibiotics to combat drug-resistant bacterial infections. Positioned to capture the benefits of research and development expertise in the U.S. together with the high-quality, low-cost discovery, preclinical and development infrastructure available in China, the company has built a pipeline of discovery and development programs for the treatment of Gram-positive bacteria, Gram-negative bacteria and fungal infections. The company has research and development facilities outside San Francisco, CA and in Shanghai.